Turn TRAIL Into Better Anticancer Therapeutic Through TRAIL Fusion Proteins

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Dec 31

PMID 39740038

Authors

Yan Wang

Xin Qian

Yubo Wang

Caiyuan Yu

Li Feng

Xiaoyan Zheng

Yaya Wang

Qiuhong Gong

Affiliations

Soon will be listed here.

Abstract

Background: TNF-related apoptosis-inducing ligand (TRAIL) belongs to the tumor necrosis factor superfamily. TRAIL selectively induces apoptosis in tumor cells while sparing normal cells, which makes it an attractive candidate for cancer therapy. Recombinant soluble TRAIL and agonistic antibodies against TRAIL receptors have demonstrated safety and tolerability in clinical trials. However, they have failed to exhibit expected clinical efficacy. Consequently, extensive research has focused on optimizing TRAIL-based therapies, with one of the most common approaches being the construction of TRAIL fusion proteins.

Methods: An extensive literature search was conducted to identify studies published over the past three decades related to TRAIL fusion proteins. These various TRAIL fusion strategies were categorized based on their effects achieved.

Results: The main fusion strategies for TRAIL include: 1. Construction of stable TRAIL trimers; 2. Enhancing the polymerization capacity of soluble TRAIL; 3. Increasing the accumulation of TRAIL at tumor sites by fusing with antibody fragments or peptides; 4. Decorating immune cells with TRAIL; 5. Prolonging the half-life of TRAIL in vivo; 6. Sensitizing cancer cells to overcome resistance to TRAIL treatment.

Conclusion: This work focuses on the progress in recombinant TRAIL fusion proteins and aims to provide more rational and effective fusion strategies to enhance the efficacy of recombinant soluble TRAIL, facilitating its translation from bench to bedside as an effective anti-cancer therapeutic.

References

Vanamee E, Faustman D . On the TRAIL of Better Therapies: Understanding TNFRSF Structure-Function. Cells. 2020; 9(3). PMC: 7140660. DOI: 10.3390/cells9030764. View

Oleary L, van der Sloot A, Reis C, Deegan S, Ryan A, Dhami S . Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. Oncogene. 2015; 35(10):1261-70. DOI: 10.1038/onc.2015.180. View

She T, Yang F, Chen S, Yang H, Tao Z, Xing H . Snoopligase-catalyzed molecular glue enables efficient generation of hyperoligomerized TRAIL variant with enhanced antitumor effect. J Control Release. 2023; 361:856-870. DOI: 10.1016/j.jconrel.2023.07.042. View

Wang Y, Lei Q, Yan Z, Shen C, Wang N . TGF3L fusion enhances the antitumor activity of TRAIL by promoting assembly into polymers. Biochem Pharmacol. 2018; 155:510-523. DOI: 10.1016/j.bcp.2018.07.035. View

Rozanov D, Savinov A, Golubkov V, Rozanova O, Postnova T, Sergienko E . Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells. Mol Cancer Ther. 2009; 8(6):1515-25. PMC: 2828983. DOI: 10.1158/1535-7163.MCT-09-0202. View

Griffith T, Wiley S, Kubin M, Sedger L, Maliszewski C, Fanger N . Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med. 1999; 189(8):1343-54. PMC: 2193036. DOI: 10.1084/jem.189.8.1343. View

Uckun F, Myers D, Qazi S, Ozer Z, Rose R, DCruz O . Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia. J Clin Invest. 2015; 125(3):1006-18. PMC: 4362237. DOI: 10.1172/JCI76610. View

Yang H, Li H, Yang F, Tao Z, Shi Q, She T . Molecular superglue-mediated higher-order assembly of TRAIL variants with superior apoptosis induction and antitumor activity. Biomaterials. 2023; 295:121994. DOI: 10.1016/j.biomaterials.2023.121994. View

Wajant H . Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation. Cancers (Basel). 2019; 11(7). PMC: 6678900. DOI: 10.3390/cancers11070954. View

10.

Pimentel J, Zhou J, Wu G . The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer. Cancers (Basel). 2023; 15(10). PMC: 10216286. DOI: 10.3390/cancers15102752. View

11.

Herbst R, Eckhardt S, Kurzrock R, Ebbinghaus S, ODwyer P, Gordon M . Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010; 28(17):2839-46. DOI: 10.1200/JCO.2009.25.1991. View

12.

Sharma S, de Vries E, Infante J, Oldenhuis C, Gietema J, Yang L . Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2013; 32(1):135-44. DOI: 10.1007/s10637-013-9952-9. View

13.

Ashkenazi A . Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2(6):420-30. DOI: 10.1038/nrc821. View

14.

Koga Y, Matsuzaki A, Suminoe A, Hattori H, Hara T . Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res. 2004; 64(3):1037-43. DOI: 10.1158/0008-5472.can-03-1808. View

15.

Sang M, Zhang J, Li B, Chen Y . TRAIL-CM4 fusion protein shows in vitro antibacterial activity and a stronger antitumor activity than solo TRAIL protein. Protein Expr Purif. 2016; 122:82-9. DOI: 10.1016/j.pep.2016.02.015. View

16.

Li F, Wang X, Wu M, Guan J, Liang Y, Liu X . Biosynthetic cell membrane vesicles to enhance TRAIL-mediated apoptosis driven by photo-triggered oxidative stress. Biomater Sci. 2022; 10(13):3547-3558. DOI: 10.1039/d2bm00599a. View

17.

Kumar S, Fairmichael C, Longley D, Turkington R . The Multiple Roles of the IAP Super-family in cancer. Pharmacol Ther. 2020; 214:107610. DOI: 10.1016/j.pharmthera.2020.107610. View

18.

ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M . A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia. 2009; 23(8):1389-97. DOI: 10.1038/leu.2009.34. View

19.

Madhumathi J, Sridevi S, Verma R . Novel TNF-related Apoptotic-inducing Ligand-based Immunotoxin for Therapeutic Targeting of CD25 Positive Leukemia. Target Oncol. 2016; 11(4):535-47. DOI: 10.1007/s11523-016-0424-y. View

20.

Duivelshof B, Murisier A, Camperi J, Fekete S, Beck A, Guillarme D . Therapeutic Fc-fusion proteins: Current analytical strategies. J Sep Sci. 2020; 44(1):35-62. DOI: 10.1002/jssc.202000765. View